Vascular and cardiac benefits of angiotensin receptor blockers

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

2000 • 8,612 citations

Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure

1991 • 8,296 citations

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

2001 • 7,165 citations

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction

1992 • 5,885 citations

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

2001 • 5,812 citations

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 • 5,471 citations

The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy

1993 • 5,296 citations

Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions

1992 • 3,708 citations

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy

2000 • 3,103 citations

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

2001 • 3,065 citations

Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease

2000 • 2,616 citations

The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes

2001 • 2,520 citations

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.

1996 • 2,456 citations

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

2000 • 2,085 citations

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1999 • 2,051 citations

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II

2000 • 1,956 citations

Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease

2001 • 1,944 citations

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure

1993 • 1,775 citations

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1997 • 1,680 citations

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 • 1,592 citations

Current Concepts of the Pathogenesis of the Acute Coronary Syndromes

2001 • 1,568 citations

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1999 • 1,472 citations

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

1998 • 1,435 citations

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

1998 • 1,333 citations

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

1993 • 1,240 citations

Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease

1996 • 1,065 citations

Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

2000 • 917 citations

Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells.

2000 • 910 citations

Structure and function of small arteries

1990 • 902 citations

Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.

1990 • 878 citations

Tissue Angiotensin and Pathobiology of Vascular Disease

2001 • 750 citations

Blood Pressure and Inflammation in Apparently Healthy Men

2001 • 714 citations

Angiotensin II type 2 receptor mediates programmed cell death.

1996 • 707 citations

Small artery structure in hypertension. Dual processes of remodeling and growth.

1993 • 645 citations

Role of NADH/NADPH Oxidase–Derived H ₂ O ₂ in Angiotensin II–Induced Vascular Hypertrophy

1998 • 616 citations

Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist Losartan

2000 • 613 citations

Reversal of Left Ventricular Hypertrophy in Essential Hypertension

1996 • 609 citations

Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1996 • 598 citations

Angiotensin II-forming pathways in normal and failing human hearts.

1990 • 585 citations

Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain

2000 • 565 citations

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

2002 • 545 citations

Angiotensin II Type 1 Receptor Blockers

2001 • 477 citations

Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System

1999 • 472 citations

Structure and Mechanical Properties of Resistance Arteries in Hypertension

2000 • 438 citations

Reactive oxygen species as mediators of angiotensin II signaling

2000 • 424 citations

Angiotensin II–Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice

2001 • 361 citations

Comparative Effect of ACE Inhibition and Angiotensin II Type 1 Receptor Antagonism on Bioavailability of Nitric Oxide in Patients With Coronary Artery Disease

2001 • 344 citations

Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension

2001 • 314 citations

State-of-the-Art Lecture

1999 • 312 citations

Effect of Antihypertensive Treatment on Small Arteries of Patients With Previously Untreated Essential Hypertension

1995 • 304 citations

Characteristics of 9194 Patients With Left Ventricular Hypertrophy

1998 • 296 citations

Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design

1999 • 295 citations

Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia

2000 • 274 citations

Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.

1994 • 268 citations

Role of Variability in Microvascular Resistance on Fractional Flow Reserve and Coronary Blood Flow Velocity Reserve in Intermediate Coronary Lesions

2001 • 262 citations

Angiotensin II Type 1 Receptor

1998 • 226 citations

Roles of Angiotensin II Type 2 Receptor Stimulation Associated With Selective Angiotensin II Type 1 Receptor Blockade With Valsartan in the Improvement of Inflammation-Induced Vascular Injury

2001 • 218 citations

Resistance Artery Mechanics, Structure, and Extracellular Components in Spontaneously Hypertensive Rats

1999 • 216 citations

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients

2000 • 202 citations

Mechanics and Composition of Human Subcutaneous Resistance Arteries in Essential Hypertension

1999 • 198 citations

Acute and Chronic Angiotensin-1 Receptor Antagonism Reverses Endothelial Dysfunction in Atherosclerosis

2000 • 196 citations

Comparison of Effects of Angiotensin I– Converting Enzyme Inhibition and β-Blockade for 2 Years on Function of Small Arteries From Hypertensive Patients

1995 • 193 citations

Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture.

1992 • 191 citations

Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design

2000 • 183 citations

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

2001 • 174 citations

Effect of the Angiotensin II Type 1 Receptor Blocker Candesartan on Endothelial Function in Patients With Essential Hypertension

2000 • 172 citations

From the hope to the ontarget and the transcend studies: challenges in improving prognosis

2002 • 171 citations

Histology of subcutaneous small arteries from patients with essential hypertension.

1993 • 171 citations

Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries

2000 • 170 citations

D Allele of the Angiotensin I–Converting Enzyme Is a Major Risk Factor for Restenosis After Coronary Stenting

1997 • 160 citations

Role of AT ₂ Receptors in Angiotensin II–Stimulated Contraction of Small Mesenteric Arteries in Young SHR

1999 • 159 citations

Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin i-converting enzyme inhibitor comparison with effects of a ?-locker

1995 • 137 citations

Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.

2001 • 135 citations

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

2001 • 133 citations

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design

1999 • 132 citations

Prothrombotic effects of angiotensin.

2000 • 126 citations

Angiotensin II type 1 receptor−153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects

2001 • 124 citations

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

2002 • 122 citations

Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

2001 • 118 citations

Regulation of Local Angiotensin II Formation in the Human Heart in the Presence of Interstitial Fluid

1997 • 117 citations

Dose-dependent effects of perindopril on blood pressure and small-artery structure.

1994 • 114 citations

Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy

1997 • 110 citations

Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats

1998 • 105 citations

Cellular Hypertrophy in Subcutaneous Small Arteries of Patients With Renovascular Hypertension

2000 • 104 citations

The Life Study

1973 • 103 citations

Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial

2001 • 98 citations

Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice

2001 • 95 citations

Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications

2001 • 93 citations

AT1 and AT2 receptors in the kidney: Role in disease and treatment

2000 • 88 citations

Widespread tissue distribution of human chymase.

1994 • 85 citations

A novel vascular smooth muscle chymase is upregulated in hypertensive rats

2001 • 85 citations

Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients.

1993 • 83 citations

Effects of Acute Angiotensin II Type 1 Receptor Antagonism and Angiotensin Converting Enzyme Inhibition on Plasma Fibrinolytic Parameters in Patients With Heart Failure

1999 • 81 citations

Effects of Low and High Doses of Fosinopril on the Structure and Function of Resistance Arteries

1995 • 79 citations

Differential Roles of AT ₁ and AT ₂ Receptor Subtypes in Vascular Trophic and Phenotypic Changes in Response to Stimulation With Angiotensin II

1997 • 78 citations

Dual pathway for angiotensin II formation in human internal mammary arteries

1998 • 78 citations

Functional Evidence for a Role of Vascular Chymase in the Production of Angiotensin II in Isolated Human Arteries

2001 • 75 citations

Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats

2002 • 73 citations

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design)

1998 • 72 citations

Reduction of resistance artery stiffness by treatment with the AT1-receptor antagonist losartan in essential hypertension

2000 • 69 citations

Significance of Chymase-Dependent Angiotensin II–Forming Pathway in the Development of Vascular Proliferation

2001 • 69 citations

The regulation of human vascular smooth muscle extracellular matrix protein production by α- and β-adrenoceptor stimulation

2002 • 68 citations

Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

2001 • 56 citations

Angiotensin type 2 receptors: potential importance in the regulation of blood pressure

2001 • 55 citations

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension

2001 • 52 citations

Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?

2001 • 50 citations

Vasoconstrictor Effect of the Angiotensin-Converting Enzyme–Resistant, Chymase-Specific Substrate [Pro ¹¹ _D -Ala ¹² ] Angiotensin I in Human Dorsal Hand Veins

2001 • 47 citations

Blockade of Angiotensin II Type 1 Receptors: Effect on Carotid and Radial Artery Structure and Function in Hypertensive Humans

2000 • 44 citations

Addressing Those Two That Go Together: The Angiotensin II Receptors and their Role in Blood-flow Regulation

2001 • 35 citations

Effect of Antihypertensive Treatment on Response to Endothelin of Resistance Arteries of Hypertensive Rats

1993 • 30 citations

Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction

2000 • 25 citations

A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension

2001 • 22 citations

Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function

2001 • 20 citations

Can Antihypertensive Drugs Reduce Atherosclerosis and Its Clinical Complications

1994 • 20 citations

Long-Term Potential of Angiotensin Receptor Blockade for Cardiovascular Protection in Hypertension: The VALUE Trial

1999 • 19 citations

Formulating clinical strategies for angiotensin antagonism: a review of preclinical and clinical studies

2001 • 13 citations

Impact of neuroendocrine activation on coronary artery disease

1998 • 9 citations

Achieving Blood Pressure Targets in the Management of Hypertension

2001 • 8 citations

Expanded role for ARBs in cardiovascular and renal disease?

2001 • 4 citations

Deleted Work

1955 • 0 citations